Structured fixed-bed bioreactors offer vaccine manufacturers a scalable, lower-cost alternative to roller bottles and microcarrier systems.
Thomas Robert
Advertisement
Thomas Robert, PhD, is senior innovation and scientific affairs lead at Univercells Technologies.
Articles by Thomas Robert
Advertisement
Latest Updated Articles
Rethinking the Cell Culture Platform Behind Vaccine ManufacturingSeptember 25th 2026
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
2
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
3
BioNTech's BNT113 Misses PFS Goal in Head and Neck Cancer Trial
4
Gilead Taps Vir Biotechnology's PRO-XTEN Tech for Solid Tumors
5